One of the major obstacles to phage clinical trials in the UK has been the requirement for GMP phages. However, regulators require that for phages to achieve GMP standards they must themselves have first been subject to clinical trials. This impasse is stalling the development of phages in the UK. The Department of Health and Social Care should consider investing in a small GMP facility which would solve one part of the problem. However, it would not solve the issue of UK GMP requiring clinical trials that in themselves had to use GMP phages. Clarity is needed on how this conundrum can be solved. (Paragraph 105) The antimicrobial potential of bacteriophages 61